Skinbiotherapeutics Share Discussion Threads

[elrico] 08/11/2017 00:01

Ouch! Meow!! ;)

[semper vigilans] 07/11/2017 21:14

Test it on women to see if it is safe for animals?

[elrico] 07/11/2017 21:07

ODR - it's not just women any more :)

[onedayrodders] 07/11/2017 20:06

The Cosmetic cream alone could be absolutely massive ... the female global spend in search of eternal youth is mouthwatering and never ending generations behind them to ensure it never ends.

Let's hope it's THE new women's best friend cosmetic product for the next century and beyond.

[rafboy] 07/11/2017 16:10

Thanks to Ray Page on L*E

Yesterdays article;
SkinBiotherapeutics readying for cosmetic cream launch after safety test success

SkinBiotix recently passed an independent in-vitro (test tube) cytotoxicity safety test with flying colours
SkinBioTherapeutics PLC (LON:SBTX) expects a study in people of a cosmetic skin care cream next year to be the start of £serious£; commercialisation talks.

Tentative discussions have already begun, Cath O£Neill, the skin microbiome specialist£s chief executive told Proactive Investors, but human data is crucial to the process.

£Human data is gold dust. The results of the study will spark a major value inflexion point from which we can start serious conversations about commercialisation.£

WATCH:SkinBioTherapeutics' Dr Cath O'Neill named one of healthcare's top movers and shakers

SkinBiotix, the company's microbiome platform, will be tested in a cosmteic consumer efficacy study, a far less demanding process than clinical trials.

Around sixty patients will be involved in the study for a month and if successful, it will be allowed on sale almost immediately.

Work on the formulation of the skin cream has also started, O£Neill said, adding this was another crucial part of the product development process.

SkinBiotix recently passed an independent in-vitro (test tube) cytotoxicity safety test with flying colours and now just has two more safety tests to clear before the human efficacy study can begin.

SkinBioTherapeutics presented data recently at a microbiome symposium sponsored by Wellcome Trust that was well received, but the human trial will be a major step forward, she added.

£Once the results [from the human study] are in we are good to go.£

SkinBiotix might be either an ingredient in someone else£s product or a brand in its own right.

O£Neill was talking to Proactive after being named among the top 50 female movers and shakers in the BioBusiness 2017 report.

She said was delighted to receive the award especially as SkinbioTherapeutics was listed in the great science category.

£SkinBioTherapeutics is founded on very robust science and is proud of its scientific heritage.£

The company is working on three applications for its microbiome-based products: cosmetics; an anti-infective and an eczema treatment.

Shares rose 1% to 10.3p.

[moormoney] 07/11/2017 15:45

At last some action 😄😄

[bobalot] 07/11/2017 15:42

Looks like its starting to break out...yippee

11.00 +0.88 (8.64%)
Real-time:   3:41PM GMT
LON real-time data - Disclaimer
Currency in GBX unless noted

Range 9.84 - 10.25
52 week 9.33 - 17.75
Open 9.84
Vol / Avg. 255,252.00/92,426.00

[rafboy] 07/11/2017 11:13

Bit of interest here this morning, good to see.

[bobalot] 06/11/2017 15:53

Really promising news about commercialisation.

SkinBiotherapeutics readying for cosmetic cream launch after safety test success

14:45 06 Nov 2017

Skinbiotex recently passed an independent in-vitro (test tube) cytotoxicity safety test with flying colours

First product will be skin care cream

SkinBioTherapeutics PLC (LON:SBTX) expects a study in people of a cosmetic skin care cream next year to be the start of ‘serious’; commercialisation talks.
Tentative discussions have already begun, Cath O’Neill, the skin microbiome specialist’s chief executive told Proactive Investors, but human data is crucial to the process.  

“Human data is gold dust. The results of the study will spark a major value inflexion point from which we can start serious conversations about commercialisation.”

Skinbiotex will tested in a consumer efficacy study, a far less demanding process than clinical trials.

Around sixty patients will be involved in the study for a month and if the cream passes successfully, it will be allowed on sale almost immediately.

Work on a formulation of the skin cream has also started, O’Neill said, adding this was another crucial part of the product development process.

Skinbiotex recently passed an independent in-vitro (test tube) cytotoxicity safety test with flying colours and now just has two more safety tests to clear before the human efficacy study can begin.

SkinBiotherapeutics presented data recently at a microbiome symposium sponsored by Wellcome Trust that was well received, but the human trial will be a major step forward, she added.

“Once the results [from the human study] are in we are good to go.”

Skinbiotex might be either an ingredient in someone else’s product or a brand in its own right.

O’Neill was talking to Proactive after being named among the top 50 female movers and shakers in the BioBusiness 2017 report.

She said was delighted to receive the award especially as Skinbiotherapeutics was listed in the great science category.

“SkiBiotherapeutics is founded on very robust science and is proud of its scientific heritage.”

The company is working on three applications for its microbiome-based products: cosmetics; an anti-infective and an eczema treatment.

Shares rose 1% to 10.3p.

www.proactiveinvestors.co.uk/companies/news/186818

[elrico] 06/11/2017 12:02

In its own sweet time - Bob ;)

[bobalot] 04/11/2017 21:24

In other words SBTX is a great investment...as a multi bagger.

[elrico] 04/11/2017 11:25

Trotters - Agreed. It seems SBTX is now making attempts to get their good progress out into the public domain. Once we have successful human data, this will significantly derisk the science and SBTX as an investment, much the same way as the parent company OPTI, as most of us know - others will catch on in due course.

There is still the matter of the 41.9% OPTI hold; now with the successful tidying up of the share register (OPTI's) this admin issue being key, now resolved, should pave the way for news on the in-specie dive due to OPTI shareholders. IMHO this is key and is partially responsible for holding SBTX back. I previously stated I expect SBTX and OPTI to trade in similar patterns until such a time key development changed this. This appears to have been the case. I fully expect OPTI to make significant progress as we head into the New Year and I expect SBTX will follow on the coattails until such a time it trades under its own commercial development in 2018. I expect some OPTI money will help this as PI take profits and buy SBTX, especially those PI's that missed out on the in-specie divi.

Happy to sit and wait developments with a keen eye, happy with my initial entry price and keenly await my bonus in-specie divi with interest. I won't be selling them, locked it or now.

[shrewdmole] 04/11/2017 08:29

Trotterstrading

I've mentioned it before but I can see Sbtx rising on the back of Opti progress too.
It's natural for investors to look at similar or connected entities on the back of successful investing.

Opti imho is about to hit the inflection point and when it does we will be well rewarded.

In the meantime I'd hazard a guess there are a couple of major potential partners being kept abreast of developments.

S

[bobalot] 03/11/2017 10:07

INCREMENTAL VALUE IS BEING ADDED TO THE PATENTS and the share price imo.

[trotterstrading] 03/11/2017 10:03

Elrico, all the news should be accretive to shareholder value, expect a strong build into the efficacy study in Q3, but patient safety trials early 2018 will also be a key milestone for industry commercial discussions, they will be keeping a close eye on proceedings

[bobalot] 02/11/2017 18:44

SBTX is a FAR bigger multi-bagger than OPTI...more cash will be made for investors at present levels of about 10p....in a few years expect SBTX to be worth 70p or more and benefiting from the market storm from OPTI.

SBTX is a NO-BRAINER share price RISER WITH SHARED OPTI MARKETING CONTACTS AND SKILLS.

[bobalot] 02/11/2017 14:01

Clinical safety trials using people will start early next year followed by a months human clinical trial in Q3 --- so safety trials are first human tests in early 2018.


This is all part and parcel of the same---- two sets of human safety trials followed by a months clinical trial. Then that will be followed with Eczma trials

see the video interview:

THE COMPANY IS MAKING RAPID PROGRESS

[elrico] 02/11/2017 13:32

Q3 is a key period then, not early 2018.

[bobalot] 02/11/2017 13:13

Nice article and video; thanks.

SkinBioTherapetics' Dr Cath O'Neill named one of healthcare's top movers and shakers
Share
10:21 02 Nov 2017


Dr Cath O'Neill, chief executive of SkinBioTherapetics PLC (LON:SBTX), caught up with Proactive Investors after being recognised as one of the top 50 female leaders in UK healthcare as part of BioBusiness' 2017 50 Movers and Shakers report.

Dr O'Neill's been recognised for her research within the skin microbiome sector.

[loungeact] 02/11/2017 11:50

SkinBioTherapetics' Dr Cath O'Neill named one of healthcare's top movers and shakers -

[bobalot] 01/11/2017 08:13

SBTX is very likely to benefit from the marketing contacts OPTI have established which could accelerate the commercialisation process after clinical trials which are due to start early in 2018.

[semper vigilans] 01/11/2017 08:08

If/when OPTI takes off, this should follow, as to some extent it is based on a similar model.

[trotterstrading] 28/10/2017 09:23

Worth noting the majority of Shareholders have a 12 month lock in period.

[5chipper] 27/10/2017 20:32

Thanks Zedder